Skip to main content

Profile hero

Profile details

About Ben Cohen

Ben is a senior associate in our intellectual property group.

Ben advises clients on IP, technology and commercial mattes, with a particular focus on the life sciences sector.

Ben's practice involves negotiating complex licensing and collaboration arrangements and other strategic alliances and advising on IP issues arising in the context of M&A, joint venture and IPOs. Ben also advises on business separation and commercial issues in the context of complex IP/tech-heavy carve-outs.

Ben's contentious experience includes the litigation and arbitration of patents, trade marks and trade secrets and IP licence disputes.

Recent work

  • Novartis on the separation and spin-off of Sandoz, its generics and biosimilars division.
  • Ontario Teachers’ Pension Plan Board on its joint investment with Nordic Capital in Advanz Pharma.
  • Hasten Biopharmaceuticals on its acquisition of the product portfolios in South East Asia from Celltrion Healthcare.
  • Recordati, a portfolio company of CVC Capital Partners, on its acquisition of EUSA Pharma (UK) Limited.
  • Universal Music Group on the IP aspects of its majority Investment in Mavin Global.
  • EdF on the IP aspects of its acquisition of part of GE Steam Power’s nuclear power business.
  • General Atlantic's BeyondNetZero on the acquisition of a minority stake in ABB E-mobility.
  • AstraZeneca on its cancer drug patent licence dispute with Tesaro.
  • Advising global telecoms company on a major, multi-jurisdictional SEP/FRAND dispute, including advising on client’s SEP portfolio vetting project.

Qualifications

University education

  • BPP University Law School – Legal Practice Course 
  • London School of Economics – LLB in Law 
  • Artificial Intelligence - Said Business School, University of Oxford 

Professional qualifications

  • Solicitor, England and Wales